EA032003B1 - Анти-tdp-43 антитело - Google Patents
Анти-tdp-43 антитело Download PDFInfo
- Publication number
- EA032003B1 EA032003B1 EA201490825A EA201490825A EA032003B1 EA 032003 B1 EA032003 B1 EA 032003B1 EA 201490825 A EA201490825 A EA 201490825A EA 201490825 A EA201490825 A EA 201490825A EA 032003 B1 EA032003 B1 EA 032003B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- seq
- tdp
- antibody
- antibodies
- amino acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Radiology & Medical Imaging (AREA)
- General Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Psychology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161553113P | 2011-10-28 | 2011-10-28 | |
| PCT/IB2012/002905 WO2013061163A2 (en) | 2011-10-28 | 2012-10-26 | Tdp-43 specific binding molecules |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| EA201490825A1 EA201490825A1 (ru) | 2015-01-30 |
| EA201490825A8 EA201490825A8 (ru) | 2016-09-30 |
| EA032003B1 true EA032003B1 (ru) | 2019-03-29 |
Family
ID=47720540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201490825A EA032003B1 (ru) | 2011-10-28 | 2012-10-26 | Анти-tdp-43 антитело |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US9587014B2 (enExample) |
| EP (2) | EP2771359B1 (enExample) |
| JP (3) | JP6240611B2 (enExample) |
| KR (2) | KR102032080B1 (enExample) |
| CN (1) | CN104159918B (enExample) |
| AU (1) | AU2012327211C9 (enExample) |
| BR (1) | BR112014010161B1 (enExample) |
| CA (2) | CA3112082A1 (enExample) |
| CL (1) | CL2014001074A1 (enExample) |
| EA (1) | EA032003B1 (enExample) |
| ES (1) | ES2883212T3 (enExample) |
| IL (2) | IL232219B (enExample) |
| MX (2) | MX357678B (enExample) |
| MY (1) | MY167795A (enExample) |
| PH (1) | PH12014500940A1 (enExample) |
| SG (1) | SG11201401735WA (enExample) |
| WO (1) | WO2013061163A2 (enExample) |
| ZA (1) | ZA201403680B (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20140049T1 (hr) | 2007-01-05 | 2014-02-28 | University Of Zürich | Anti beta-amiloid antitijela i njihova upotreba |
| ES2883212T3 (es) | 2011-10-28 | 2021-12-07 | Biogen Int Neuroscience Gmbh | Moléculas de unión específica a TDP-43 |
| CN105593240B (zh) * | 2013-06-11 | 2024-05-31 | 保罗·谢勒学院 | 用于以单氨基酸分辨率确定可突变配体-gpcr结合的方法以及突变配体和gpcr对 |
| EP3099712A4 (en) * | 2014-01-31 | 2017-11-08 | Arizona Board of Regents on behalf of Arizona State University | Antibody based reagents that specifically recognize neurodegenerative disease related forms of the protein tdp-43 |
| CN107074937B (zh) | 2014-07-29 | 2021-07-27 | 神经免疫控股公司 | 人源抗亨廷顿蛋白(htt)抗体及其用途 |
| CN104497121A (zh) * | 2014-08-29 | 2015-04-08 | 苏州顺升桥生物科技有限公司 | 淀粉样蛋白tdp-43及其用途 |
| TWI592423B (zh) * | 2014-10-03 | 2017-07-21 | 中央研究院 | 可辨識致病性ｔｄｐ－４３之抗體及其用途 |
| US9796778B1 (en) | 2014-10-03 | 2017-10-24 | Academia Sinica | Antibodies against pathological forms of TDP-43 and uses thereof |
| WO2016053610A1 (en) * | 2014-10-03 | 2016-04-07 | Academia Sinica | Antibodies against pathological forms of tdp-43 and uses thereof |
| MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
| WO2016196324A1 (en) | 2015-05-29 | 2016-12-08 | University Of Floridia Research Foundation, Inc. | Methods for diagnosing huntington's disease |
| WO2017111166A1 (ja) * | 2015-12-25 | 2017-06-29 | 国立大学法人東京農工大学 | Ｔｄｐ－４３細胞内存在量関連疾患治療剤 |
| US11340225B2 (en) | 2016-03-14 | 2022-05-24 | Biogen International Neuroscience Gmbh | Antibody-dependent cell-mediated phagocytosis assay for reliably measuring uptake of aggregated proteins |
| US10940161B2 (en) | 2016-04-04 | 2021-03-09 | University Of Florida Research Foundation, Incorporated | Manipulation of EIF3 to modulate repeat associated non-ATG (RAN) translation |
| MA45715A (fr) | 2016-07-25 | 2019-05-29 | Biogen Ma Inc | Anticorps anti-hspa5 (grp78) et leurs utilisations |
| MA47163A (fr) | 2016-12-16 | 2019-11-06 | Biogen Ma Inc | Facteur 11 de différenciation de croissance activé protéolytiquement stabilisé |
| SG11201907848YA (en) | 2017-03-14 | 2019-09-27 | Five Prime Therapeutics Inc | Antibodies binding to vista at acidic ph |
| JP7526455B2 (ja) | 2017-04-17 | 2024-08-01 | ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． | ＰＫＲおよびｅＩＦ２Ａ－Ｐ経路によるＲＡＮタンパク質翻訳の調節 |
| US11214613B2 (en) | 2017-05-30 | 2022-01-04 | The University Of British Columbia | Epitopes in the RNA recognition motif 1 (RRM1) of TDP-43 and misfolding-selective antibodies thereto |
| SI3672631T1 (sl) | 2017-08-22 | 2023-06-30 | Biogen Ma Inc. | Farmacevtski sestavki, ki vsebujejo protitelesa proti beta amiloidu |
| WO2019118527A1 (en) * | 2017-12-14 | 2019-06-20 | The Johns Hopkins University | Novel anti-fungal inhibitors |
| WO2019113711A1 (en) | 2017-12-14 | 2019-06-20 | University Of Ottawa | Exosome packaging and targeted autophagy |
| WO2019134981A1 (en) * | 2018-01-05 | 2019-07-11 | Ac Immune Sa | Misfolded tdp-43 binding molecules |
| CN112236523A (zh) | 2018-03-16 | 2021-01-15 | 国立大学法人滋贺医科大学 | 降解和去除异常tdp-43的抗体片段 |
| MX2020009786A (es) | 2018-03-21 | 2020-10-12 | Five Prime Therapeutics Inc | Anticuerpos de union a supresor de la activacion de celulas t que contiene el dominio variable de inmunoglobulina (vista) a ph acido. |
| TW202019398A (zh) * | 2018-06-28 | 2020-06-01 | 張翔毓 | 用於治療或預防構形疾病之方法及藥物篩選方法 |
| US12091462B2 (en) | 2018-07-11 | 2024-09-17 | Five Prime Therapeutics, Inc. | Antibodies binding to vista at acidic pH |
| EA202191179A1 (ru) | 2018-10-29 | 2021-09-09 | Байоджен Ма Инк. | Гуманизированные и стабилизированные варианты fc5 для улучшения транспорта через гематоэнцефалический барьер |
| JP2022512388A (ja) * | 2018-12-14 | 2022-02-03 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | ミスフォールドｔｄｐ－４３に対する抗体およびその使用方法 |
| CA3137882A1 (en) | 2019-05-23 | 2020-11-26 | Tamara SEREDENINA | Anti-tdp-43 binding molecules and uses thereof |
| AU2020331401B2 (en) * | 2019-08-12 | 2025-04-24 | Celosia Therapeutics Pty Ltd | Compositions and methods for treatment |
| JP7620988B2 (ja) * | 2019-09-20 | 2025-01-24 | ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． | 血清および組織ライセートからのｒａｎタンパク質に対する抗体の検出 |
| GB202004863D0 (en) * | 2020-04-02 | 2020-05-20 | Univ Oxford Innovation Ltd | Method |
| KR20230025659A (ko) | 2020-04-28 | 2023-02-22 | 솔라 바이오사이언시즈 엘엘씨 | Tdp-43 단백질병증의 치료를 위한 조성물 및 방법 |
| WO2021217267A1 (en) * | 2020-04-29 | 2021-11-04 | The University Of British Columbia | Single chain antibodies and intrabodies to misfolded tdp-43 and methods of use |
| JP2023547580A (ja) * | 2020-07-06 | 2023-11-13 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティ オブ テキサス システム | Ｔｄｐ－４３バイオセンサー細胞株 |
| JP2023537761A (ja) * | 2020-08-14 | 2023-09-05 | エイシー イミューン ソシエテ アノニム | ヒト化抗ｔｄｐ－４３結合分子およびその使用 |
| US20240003918A1 (en) | 2020-11-30 | 2024-01-04 | Enigma Biointelligence, Inc. | Non-invasive assessment of alzheimer's disease |
| EP4286406A4 (en) | 2021-01-29 | 2025-07-23 | Illimis Therapeutics Inc | FUSION MOLECULE WITH NON-INFLAMMATORY PHAGOCYTOSIS-INDUCING ACTIVITY |
| CN112920264B (zh) * | 2021-02-08 | 2022-07-05 | 武汉大学 | Tdp-43蛋白的o-糖基化突变体及其应用 |
| JP6961278B1 (ja) * | 2021-03-10 | 2021-11-05 | 国立研究開発法人量子科学技術研究開発機構 | 生体試料中のｔｄｐ−４３を測定する方法及び装置 |
| EP4351624A4 (en) * | 2021-05-27 | 2025-02-19 | Mayo Foundation for Medical Education and Research | METHODS AND MATERIALS FOR THE TREATMENT OF PROTEINOPATHIES |
| US20230107901A1 (en) * | 2021-10-01 | 2023-04-06 | University Of Utah Research Foundation | Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy |
| CA3239708A1 (en) | 2021-12-03 | 2023-06-08 | Aubin MICHALON | Novel potency assay for antibody-based drugs and useful means therefor |
| CR20240378A (es) | 2022-02-16 | 2024-10-03 | Ac Immune Sa | Moléculas de unión anti -tdp-43 humanizadas y usos de las mismas |
| WO2023194565A1 (en) * | 2022-04-08 | 2023-10-12 | Ac Immune Sa | Anti-tdp-43 binding molecules |
| WO2023205579A1 (en) * | 2022-04-18 | 2023-10-26 | The Regents Of The University Of California | Compositions and methods for disrupting pathological aggregates |
| US20250263454A1 (en) | 2022-04-22 | 2025-08-21 | Niigata University | Aggregation inhibitor of tdp-43 and pharmaceutical composition |
| CN120917043A (zh) | 2023-03-08 | 2025-11-07 | Ac免疫有限公司 | 抗tdp-43结合分子及其用途 |
| WO2024263701A1 (en) * | 2023-06-20 | 2024-12-26 | The Trustees Of Dartmouth College | Chimeric antigen receptors (cars) targeting tdp43, tregs expressing said cars, and use thereof for the treatment of als, ftd and ad |
| KR102859015B1 (ko) * | 2023-07-20 | 2025-09-12 | 충북대학교 산학협력단 | ｃＡｂｌ에 의한 ＴＤＰ４３의 특이적 인산화 분석을 통한 신경퇴행성 질환을 진단하는 방법 및 이를 이용한 신경퇴행성 질환의 치료제 스크리닝 방법 |
| CN116875738A (zh) * | 2023-07-24 | 2023-10-13 | 山东省农业科学院畜牧兽医研究所 | 一种鉴定牛tdp-43基因启动子活性区域的方法 |
| WO2025059486A1 (en) * | 2023-09-15 | 2025-03-20 | Prothena Biosciences Limited | Anti-tdp-43 antibodies and uses thereof |
| WO2025186332A1 (en) | 2024-03-05 | 2025-09-12 | Ac Immune Sa | Vectorized anti-tdp-43 antibodies |
| CN119331085B (zh) * | 2024-10-16 | 2025-03-14 | 中国科学院合肥物质科学研究院 | 沙贝冠状病毒广谱中和抗体及其应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5688511A (en) * | 1991-11-05 | 1997-11-18 | Board Of Regents, The University Of Texas System | Cellular protein TDP-43 and regulation of HIV-1 gene expression |
| WO2008081008A1 (en) * | 2007-01-05 | 2008-07-10 | University Of Zurich | Method of providing disease-specific binding molecules and targets |
| WO2009099941A2 (en) * | 2008-02-01 | 2009-08-13 | Washington University In St. Louis | Sequences associated with tdp-43 proteinopathies and methods of using the same |
| CN101634656A (zh) * | 2009-08-21 | 2010-01-27 | 武汉三鹰生物技术有限公司 | 人tdp-43的单抗包被酶标板的制法及elisa检测试剂盒 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2253633A1 (en) * | 1997-12-03 | 1999-06-03 | Boehringer Mannheim Corporation | Complex specific antibodies, method of preparation and uses thereof |
| US8354236B2 (en) * | 2006-09-29 | 2013-01-15 | The Trustees Of The University Of Pennsylvania | Detection of neurodegenerative disease |
| WO2008151055A1 (en) | 2007-06-01 | 2008-12-11 | Mayo Foundation For Medical Education And Research | Diagnosing neurodegenerative diseases |
| EP2189526B1 (en) * | 2007-07-06 | 2013-09-04 | Tokyo Metropolitan Institute of Medical Science | Antibody binding specifically to tdp-43 aggregate |
| WO2010069603A1 (en) | 2008-12-19 | 2010-06-24 | Neurimmune Therapeutics Ag | Human anti-alpha-synuclein autoantibodies |
| ES2883212T3 (es) | 2011-10-28 | 2021-12-07 | Biogen Int Neuroscience Gmbh | Moléculas de unión específica a TDP-43 |
-
2012
- 2012-10-26 ES ES12824769T patent/ES2883212T3/es active Active
- 2012-10-26 CN CN201280064098.6A patent/CN104159918B/zh not_active Expired - Fee Related
- 2012-10-26 BR BR112014010161-2A patent/BR112014010161B1/pt not_active IP Right Cessation
- 2012-10-26 PH PH1/2014/500940A patent/PH12014500940A1/en unknown
- 2012-10-26 AU AU2012327211A patent/AU2012327211C9/en not_active Ceased
- 2012-10-26 CA CA3112082A patent/CA3112082A1/en active Pending
- 2012-10-26 WO PCT/IB2012/002905 patent/WO2013061163A2/en not_active Ceased
- 2012-10-26 KR KR1020187035073A patent/KR102032080B1/ko not_active Expired - Fee Related
- 2012-10-26 MY MYPI2014001180A patent/MY167795A/en unknown
- 2012-10-26 US US14/354,404 patent/US9587014B2/en not_active Expired - Fee Related
- 2012-10-26 EA EA201490825A patent/EA032003B1/ru unknown
- 2012-10-26 KR KR1020147014139A patent/KR101961508B1/ko active Active
- 2012-10-26 JP JP2014537750A patent/JP6240611B2/ja not_active Expired - Fee Related
- 2012-10-26 EP EP12824769.9A patent/EP2771359B1/en active Active
- 2012-10-26 EP EP21173838.0A patent/EP3964524A1/en not_active Withdrawn
- 2012-10-26 MX MX2014005048A patent/MX357678B/es active IP Right Grant
- 2012-10-26 CA CA2853412A patent/CA2853412C/en active Active
- 2012-10-26 SG SG11201401735WA patent/SG11201401735WA/en unknown
-
2014
- 2014-04-24 IL IL23221914A patent/IL232219B/en active IP Right Grant
- 2014-04-25 MX MX2018008680A patent/MX2018008680A/es unknown
- 2014-04-25 CL CL2014001074A patent/CL2014001074A1/es unknown
- 2014-05-20 ZA ZA2014/03680A patent/ZA201403680B/en unknown
-
2016
- 2016-11-04 US US15/343,450 patent/US10259866B2/en active Active
-
2017
- 2017-06-28 JP JP2017126314A patent/JP6417451B2/ja not_active Expired - Fee Related
-
2018
- 2018-09-19 JP JP2018174683A patent/JP6652609B2/ja not_active Expired - Fee Related
-
2019
- 2019-02-25 US US16/284,602 patent/US11091540B2/en not_active Expired - Fee Related
- 2019-10-28 IL IL270223A patent/IL270223B/en active IP Right Grant
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5688511A (en) * | 1991-11-05 | 1997-11-18 | Board Of Regents, The University Of Texas System | Cellular protein TDP-43 and regulation of HIV-1 gene expression |
| WO2008081008A1 (en) * | 2007-01-05 | 2008-07-10 | University Of Zurich | Method of providing disease-specific binding molecules and targets |
| WO2009099941A2 (en) * | 2008-02-01 | 2009-08-13 | Washington University In St. Louis | Sequences associated with tdp-43 proteinopathies and methods of using the same |
| CN101634656A (zh) * | 2009-08-21 | 2010-01-27 | 武汉三鹰生物技术有限公司 | 人tdp-43的单抗包被酶标板的制法及elisa检测试剂盒 |
Non-Patent Citations (4)
| Title |
|---|
| "Biogen Idec and Neurimmune Announce Agreement on Three Neurodegenerative Disease Programs", 20 December 2010 (2010-12-20), XP055064808, Retrieved from the Internet: URL:http://www.businesswire.com/news/home/20101220006526/en/Biogen-Idec-Neurimmune-Announce-Agreement-Neurodegenerative-Disease [retrieved on 2013-05-31], the whole document * |
| "TARDBP (41-7.1): sc-100871", 26 March 2009 (2009-03-26), XP055064934, Retrieved from the Internet: URL:http://datasheets.scbt.com/sc-100871.pdf [retrieved on 2013-06-03], the whole document * |
| JOHNSON B.S. ET AL.,: "a yeast TDP-43 proteinopathy model: exploring the molecular determinants of TDP-43 aggregation and cellular toxicity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, NATIONAL ACADEMY OF SCIENCES, US, vol. 105, no. 17, 29 April 2008 (2008-04-29), US, pages 6439 - 6444, XP002534604, ISSN: 0027-8424, DOI: 10.1073/PNAS.0802082105 * |
| YUKI SHIINA ; KUNIMASA ARIMA ; HIROKO TABUNOKI ; JUN-ICHI SATOH: "TDP-43 Dimerizes in Human Cells in Culture", CELLULAR AND MOLECULAR NEUROBIOLOGY, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NE, vol. 30, no. 4, 31 December 2009 (2009-12-31), Ne, pages 641 - 652, XP019815449, ISSN: 1573-6830 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102032080B1 (ko) | Tdp-43 특이적 결합 분자 | |
| US12234281B2 (en) | Antibody-based therapy of transthyretin (TTR) amyloidosis and human-derived antibodies therefor | |
| US11352441B2 (en) | Human anti-SOD1 antibodies | |
| AU2013361107B2 (en) | Human anti-tau antibodies | |
| AU2012327211B9 (en) | TDP-43 specific binding molecules | |
| KR102594327B1 (ko) | 인간-유래의 항-디펩티드 반복체(dpr) 항체 | |
| EA031698B1 (ru) | Человеческие анти-тау антитела | |
| KR102802736B1 (ko) | Ilt7 결합 분자 및 이의 사용 방법 | |
| HK40069392A (en) | Tdp-43 specific binding molecules | |
| HK1201846B (en) | Tdp-43 specific binding molecules |